Posts Tagged ‘Department of Insurance’s Office of Value-Based Health Care Delivery’

Use of GLP-1 medications — widely prescribed for Type 2 diabetes and obesity — nearly doubled among Delaware’s fully insured commercial members between 2020 and 2023, according to a first-of-its-kind analysis released by the Department of Insurance’s Office of Value-Based Health Care Delivery. The review found that while utilization increased sharply, the expense of the…